BENSALEM, Pa.--(BUSINESS WIRE)--
Law Offices of Howard G. Smith announces an investigation on behalf of Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) investors concerning the Company and its officers’ possible violations of federal securities laws. Investors with losses exceeding $100,000 are encouraged to contact the firm.
On December 17, 2018, FDAnews published an article reporting that “[t]he FDA cited Immunomedics for a host of violations – including its handling of a data integrity breach – observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article further reported that the breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”
On this news, Immunomedics’ share price fell $0.87, or approximately 4.6%, to close at $17.86 per share on December 17, 2018, thereby injuring investors.
If you purchased Immunomedics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.